PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
August 17 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company")
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals is pleased to announce that the United States
Patent and Trademark Office (USPTO) has issued a notice of
allowance for a patent application related to the Company’s
proprietary biocompatible protein-based particles. The broad scope
of the issued claims in this patent, entitled “Biocompatible
Protein-Based Particles and Methods Thereof” provides protection
for a broad range of proprietary products, including the
biocompatible sponge-like particles used in PetVivo’s signature
product, Spryng™ with OsteoCushion™ Technology.
“Our biocompatible particulate technology and
the claims to be issued in this patent application provides
extremely comprehensive coverage. This patent increases the scope
of our patent claims thereby expanding our competitive advantage in
the commercialization of products used in the treatment of humans
and companion animals,” stated PetVivo Chief Executive Officer,
John Lai.
With the imminent patent issuance by the USPTO,
PetVivo’s intellectual property portfolio has grown to twenty
allowed patents, ten of which are United States patents.
PetVivo diligently protects its proprietary
technologies, including the fabricated biomaterials and their
application in end products and devices. To maximize the strength
and value of its intellectual property, the claims pursued by
PetVivo generally cover the commercial devices/therapeutics, the
manufacturing methods and the methods of use of PetVivo’s
proprietary technology.
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email: info1@petvivo.com(952)
405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From May 2024 to Jun 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Jun 2023 to Jun 2024